- Home
- BOW vs COLL Comparison
BOW vs COLL Comparison
Compare BOW & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- COLL
- Stock Information
- Founded
- BOW 2020
- COLL 2002
- Country
- BOW United States
- COLL United States
- Employees
- BOW N/A
- COLL N/A
- Industry
- BOW Property-Casualty Insurers
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- COLL Health Care
- Exchange
- BOW Nasdaq
- COLL Nasdaq
- Market Cap
- BOW 1.1B
- COLL 1.0B
- IPO Year
- BOW 2024
- COLL 2015
- Fundamental
- Price
- BOW $32.97
- COLL $30.72
- Analyst Decision
- BOW Hold
- COLL Strong Buy
- Analyst Count
- BOW 5
- COLL 5
- Target Price
- BOW $33.60
- COLL $43.60
- AVG Volume (30 Days)
- BOW 95.3K
- COLL 441.9K
- Earning Date
- BOW 02-15-2025
- COLL 02-20-2025
- Dividend Yield
- BOW N/A
- COLL N/A
- EPS Growth
- BOW 130.44
- COLL 757.11
- EPS
- BOW 1.08
- COLL 2.16
- Revenue
- BOW $389,135,000.00
- COLL $599,245,000.00
- Revenue This Year
- BOW N/A
- COLL $13.25
- Revenue Next Year
- BOW $26.70
- COLL $18.14
- P/E Ratio
- BOW $30.70
- COLL $14.24
- Revenue Growth
- BOW 107.43
- COLL 9.62
- 52 Week Low
- BOW $22.14
- COLL $28.39
- 52 Week High
- BOW $37.81
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- COLL 45.90
- Support Level
- BOW N/A
- COLL $32.28
- Resistance Level
- BOW N/A
- COLL $33.45
- Average True Range (ATR)
- BOW 0.00
- COLL 1.07
- MACD
- BOW 0.00
- COLL -0.16
- Stochastic Oscillator
- BOW 0.00
- COLL 2.05
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc is engaged in providing specialty P&C products. It is a specialty insurance group that generates revenues by underwriting and offering a variety of specialty insurance products to domestic markets through three distinct underwriting divisions: Casualty, Professional Liability and Healthcare. Casualty specialize in GL coverage for risks in the construction, distribution, heavy manufacturing, real estate and hospitality segments and also consider underwriting risks in a broader range of industries. Key revenue is generated from Casualty segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.